Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback